Related Experiment Videos
Beta-blockers and depression after myocardial infarction: a multicenter prospective study
Joost P van Melle1, Daniëlle E P Verbeek, Maarten P van den Berg
1Department of Cardiology, Thoraxcenter, University Medical Center Groningen, Groningen, The Netherlands. j.p.van.melle@med.umcg.nl
Journal of the American College of Cardiology
|December 13, 2006
Summary
Beta-blocker use in myocardial infarction (MI) patients did not increase depression in the first year post-MI. However, long-term use or higher doses may be linked to increased depressive symptoms.
Area of Science:
- Cardiology
- Psychiatry
- Pharmacology
Background:
- Previous studies suggest a link between beta-blockers and depression, but with methodological limitations.
- Understanding this relationship is crucial for managing cardiovascular patients.
Purpose of the Study:
- To prospectively investigate the association between beta-blocker use and depression in myocardial infarction (MI) patients.
Main Methods:
- A multicenter study matched MI patients based on demographics, baseline depression, and cardiac function.
- Patients were assessed for depressive symptoms (Beck Depression Inventory) and depressive disorder (Composite International Diagnostic Interview) at multiple time points post-MI.
Main Results:
- No significant differences in depressive symptoms or disorders were found between beta-blocker users and non-users in the first year after MI.
- Confounder control did not change these results.
- A trend towards increased depressive symptoms was observed with long-term beta-blocker use and higher dosages.
Conclusions:
- Beta-blocker prescription is not associated with increased depression in the first year post-MI.
- The potential for long-term or high-dose effects on mood cannot be excluded.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...